The role of leukotrienes in allergic diseases

Allergology International

Volumn 64, Issue 1, 2015, Pages 17-26

  Liu, Min ^a,b   Yokomizo, Takehiko ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Allergic diseases; CysLTs; Leukotrienes; Lipid mediators; LTB4

Indexed keywords

ACETYLSALICYLIC ACID; LEUKOTRIENE B4; LEUKOTRIENE DERIVATIVE; SLOW REACTING SUBSTANCE; ARACHIDONATE 5 LIPOXYGENASE; CYSTEINE; CYSTEINYL-LEUKOTRIENE; LEUKOTRIENE; LEUKOTRIENE B4 RECEPTOR;

ALLERGIC CONJUNCTIVITIS; ALLERGIC DISEASE; ALLERGIC RHINITIS; ALZHEIMER DISEASE; ANAPHYLAXIS; ASPIRIN EXACERBATED RESPIRATORY DISEASE; ATOPIC DERMATITIS; EXERCISE INDUCED ASTHMA; GENERAL PATHOLOGY; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; HYPERSENSITIVITY; IMMUNOLOGY; METABOLISM;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; CYSTEINE; HUMANS; HYPERSENSITIVITY; LEUKOTRIENE B4; LEUKOTRIENES; METABOLIC NETWORKS AND PATHWAYS; RECEPTORS, LEUKOTRIENE B4;

EID: 84937512929     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.1016/j.alit.2014.09.001     Document Type: Review

References (202)

1. 1 Luster, A.D., Tager, A.M., T-cell trafficking in asthma: lipid mediators grease the way. Nat Rev Immunol 4 (2004), 711–724.
2. 2 Yokomizo, T., Izumi, T., Shimizu, T., Leukotriene B4: metabolism and signal transduction. Arch Biochem Biophys 385 (2001), 231–241.
3. 3 Samuelsson, B., Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 220 (1983), 568–575.
4. 4 Back, M., Dahlén, S.E., Drazen, J.M., Evans, J.F., Serhan, C.N., Shimizu, T., et al. International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions. Pharmacol Rev 63 (2011), 539–584.
5. 5 Ohnishi, H., Miyahara, N., Dakhama, A., Takeda, K., Mathis, S., Haribabu, B., et al. Corticosteroids enhance CD8+ T cell-mediated airway hyperresponsiveness and allergic inflammation by upregulating leukotriene B4 receptor 1. J Allergy Clin Immunol 121 (2008), 864–871 e4.
6. 6 Kudo, I., Murakami, M., Phospholipase A2 enzymes. Prostagl Other Lipid Mediat 68–69 (2002), 3–58.
7. 7 Schaloske, R.H., Dennis, E.A., The phospholipase A2 superfamily and its group numbering system. Biochim Biophys Acta 1761 (2006), 1246–1259.
8. 8 Shimizu, T., Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu Rev Pharmacol Toxicol 49 (2009), 123–150.
9. 9 Samuelsson, B., Dahlen, S.E., Lindgren, J.A., Rouzer, C.A., Serhan, C.N., Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237 (1987), 1171–1176.
10. 10 Radmark, O., Werz, O., Steinhilber, D., Samuelsson, B., 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem Sci 32 (2007), 332–341.
11. 11 Shimizu, T., Radmark, O., Samuelsson, B., Enzyme with dual lipoxygenase activities catalyzes leukotriene A4 synthesis from arachidonic acid. Proc Natl Acad Sci U S A 81 (1984), 689–693.
12. 12 Haeggstrom, J.Z., Leukotriene A4 hydrolase/aminopeptidase, the gatekeeper of chemotactic leukotriene B4 biosynthesis. J Biol Chem 279 (2004), 50639–50642.
13. 13 Haeggstrom, J.Z., Wetterholm, A., Medina, J.F., Samuelsson, B., Leukotriene A4 hydrolase: structural and functional properties of the active center. J Lipid Mediat 6 (1993), 1–13.
14. 14 Mancini, J.A., Evans, J.F., Cloning and characterization of the human leukotriene A4 hydrolase gene. Eur J Biochem 231 (1995), 65–71.
15. 15 Minami, M., Ohno, S., Kawasaki, H., Rådmark, O., Samuelsson, B., Jörnvall, H., et al. Molecular cloning of a cDNA coding for human leukotriene A4 hydrolase. Complete primary structure of an enzyme involved in eicosanoid synthesis. J Biol Chem 262 (1987), 13873–13876.
16. 16 Ohishi, N., Izumi, T., Minami, M., Kitamura, S., Seyama, Y., Ohkawa, S., et al. Leukotriene A4 hydrolase in the human lung. Inactivation of the enzyme with leukotriene A4 isomers. J Biol Chem 262 (1987), 10200–10205.
17. 17 Lam, B.K., Penrose, J.F., Freeman, G.J., Austen, K.F., Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4. Proc Natl Acad Sci U S A 91 (1994), 7663–7667.
18. 18 Martinez Molina, D., Wetterholm, A., Kohl, A., McCarthy, A.A., Niegowski, D., Ohlson, E., et al. Structural basis for synthesis of inflammatory mediators by human leukotriene C4 synthase. Nature 448 (2007), 613–616.
19. 19 Welsch, D.J., Creely, D.P., Hauser, S.D., Mathis, K.J., Krivi, G.G., Isakson, P.C., Molecular cloning and expression of human leukotriene-C4 synthase. Proc Natl Acad Sci U S A 91 (1994), 9745–9749.
20. 20 Maclouf, J., Antoine, C., Henson, P.M., Murphy, R.C., Leukotriene C4 formation by transcellular biosynthesis. Ann N Y Acad Sci 714 (1994), 143–150.
21. 21 Chen, X.S., Sheller, J.R., Johnson, E.N., Funk, C.D., Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature 372 (1994), 179–182.
22. 22 Funk, C.D., Chen, X.S., 5-Lipoxygenase and leukotrienes. Transgenic mouse and nuclear targeting studies. Am J Respir Crit Care Med 161 (2000), S120–S124.
23. 23 Goulet, J.L., Snouwaert, J.N., Latour, A.M., Coffman, T.M., Koller, B.H., Altered inflammatory responses in leukotriene-deficient mice. Proc Natl Acad Sci U S A 91 (1994), 12852–12856.
24. 24 Irvin, C.G., Tu, Y.P., Sheller, J.R., Funk, C.D., 5-Lipoxygenase products are necessary for ovalbumin-induced airway responsiveness in mice. Am J Physiol 272 (1997), L1053–L1058.
25. 25 Byrum, R.S., Goulet, J.L., Snouwaert, J.N., Griffiths, R.J., Koller, B.H., Determination of the contribution of cysteinyl leukotrienes and leukotriene B4 in acute inflammatory responses using 5-lipoxygenase- and leukotriene A4 hydrolase-deficient mice. J Immunol 163 (1999), 6810–6819.
26. 26 Berger, W., De Chandt, M.T., Cairns, C.B., Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease. Int J Clin Pract 61 (2007), 663–676.
27. 27 Carter, G.W., Young, P.R., Albert, D.H., Bouska, J., Dyer, R., Bell, R.L., et al. 5-lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther 256 (1991), 929–937.
28. 28 Fischer, A.R., McFadden, C.A., Frantz, R., Awni, W.M., Cohn, J., Drazen, J.M., et al. Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects. Am J Respir Crit Care Med 152 (1995), 1203–1207.
29. 29 Israel, E., Cohn, J., Dubé, L., Drazen, J.M., Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. J Am Med Assoc 275 (1996), 931–936.
30. 30 Knapp, H.R., Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N Engl J Med 323 (1990), 1745–1748.
31. 31 Meltzer, S.S., Hasday, J.D., Cohn, J., Bleecker, E.R., Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. Am J Respir Crit Care Med 153 (1996), 931–935.
32. 32 Niegowski, D., Kleinschmidt, T., Ahmad, S., Qureshi, A.A., Mårback, M., Rinaldo-Matthis, A., et al. Structure and inhibition of mouse leukotriene c4 synthase. PLoS One, 9, 2014, e96763.
33. 33 Niegowski, D., Kleinschmidt, T., Olsson, U., Ahmad, S., Rinaldo-Matthis, A., Haeggström, J.Z., Crystal structures of leukotriene C4 synthase in complex with product analogs: implications for the enzyme mechanism. J Biol Chem 289 (2014), 5199–5207.
34. 34 Dahlen, B., Kumlin, M., Ihre, E., Zetterstrom, O., Dahlen, S.E., Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAYx 1005. Thorax 52 (1997), 342–347.
35. 35 Diamant, Z., Timmers, M.C., van der Veen, H., Friedman, B.S., De Smet, M., Depré, M., et al. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J Allergy Clin Immunol 95 (1995), 42–51.
36. 36 Fischer, A.R., Rosenberg, M.A., Roth, M., Loper, M., Jungerwirth, S., Israel, E., Effect of a novel 5-lipoxygenase activating protein inhibitor, BAYx 1005, on asthma induced by cold dry air. Thorax 52 (1997), 1074–1077.
37. 37 Friedman, B.S., Bel, E.H., Buntinx, A., Tanaka, W., Han, Y.H., Shingo, S., et al. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am Rev Respir Dis 147 (1993), 839–844.
38. 38 Hamilton, A.L., Watson, R.M., Wyile, G., O'Byrne, P.M., Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005. Thorax 52 (1997), 348–354.
39. 39 Sampson, A.P., FLAP inhibitors for the treatment of inflammatory diseases. Curr Opin Investig Drugs 10 (2009), 1163–1172.
40. 40 Ford-Hutchinson, A.W., Bray, M.A., Doig, M.V., Shipley, M.E., Smith, M.J., Leukotriene, B., A potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 286 (1980), 264–265.
41. 41 Palmer, R.M., Stepney, R.J., Higgs, G.A., Eakins, K.E., Chemokinetic activity of arachidonic and lipoxygenase products on leuocyctes of different species. Prostaglandins 20 (1980), 411–418.
42. 42 Huang, W.W., Garcia-Zepeda, E.A., Sauty, A., Oettgen, H.C., Rothenberg, M.E., Luster, A.D., Molecular and biological characterization of the murine leukotriene B4 receptor expressed on eosinophils. J Exp Med 188 (1998), 1063–1074.
43. 43 Serhan, C.N., Prescott, S.M., The scent of a phagocyte: advances on leukotriene b(4) receptors. J Exp Med 192 (2000), F5–F8.
44. 44 Miyahara, N., Ohnishi, H., Matsuda, H., Miyahara, S., Takeda, K., Koya, T., et al. Leukotriene B4 receptor 1 expression on dendritic cells is required for the development of Th2 responses and allergen-induced airway hyperresponsiveness. J Immunol 181 (2008), 1170–1178.
45. 45 Tager, A.M., Dufour, J.H., Goodarzi, K., Bercury, S.D., von Andrian, U.H., Luster, A.D., BLTR mediates leukotriene B(4)-induced chemotaxis and adhesion and plays a dominant role in eosinophil accumulation in a murine model of peritonitis. J Exp Med 192 (2000), 439–446.
46. 46 Gijon, M.A., Zarini, S., Murphy, R.C., Biosynthesis of eicosanoids and transcellular metabolism of leukotrienes in murine bone marrow cells. J Lipid Res 48 (2007), 716–725.
47. 47 Murphy, R.C., Gijon, M.A., Biosynthesis and metabolism of leukotrienes. Biochem J 405 (2007), 379–395.
48. 48 Yokomizo, T., Izumi, T., Takahashi, T., Kasama, T., Kobayashi, Y., Sato, F., et al. Enzymatic inactivation of leukotriene B4 by a novel enzyme found in the porcine kidney. Purification and properties of leukotriene B4 12-hydroxydehydrogenase. J Biol Chem 268 (1993), 18128–18135.
49. 49 Yokomizo, T., Ogawa, Y., Uozumi, N., Kume, K., Izumi, T., Shimizu, T., cDNA cloning, expression, and mutagenesis study of leukotriene B4 12-hydroxydehydrogenase. J Biol Chem 271 (1996), 2844–2850.
50. 50 Yokomizo, T., Izumi, T., Chang, K., Takuwa, Y., Shimizu, T.A., G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 387 (1997), 620–624.
51. 51 Kamohara, M., Takasaki, J., Matsumoto, M., Saito, T., Ohishi, T., Ishii, H., et al. Molecular cloning and characterization of another leukotriene B4 receptor. J Biol Chem 275 (2000), 27000–27004.
52. 52 Yokomizo, T., Kato, K., Terawaki, K., Izumi, T., Shimizu, T., A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med 192 (2000), 421–432.
53. 53 Devchand, P.R., Keller, H., Peters, J.M., Vazquez, M., Gonzalez, F.J., Wahli, W., The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 384 (1996), 39–43.
54. 54 Yokomizo, T., Kato, K., Hagiya, H., Izumi, T., Shimizu, T., Hydroxyeicosanoids bind to and activate the low affinity leukotriene B4 receptor, BLT2. J Biol Chem 276 (2001), 12454–12459.
55. 55 Okuno, T., Iizuka, Y., Okazaki, H., Yokomizo, T., Taguchi, R., Shimizu, T., 12(S)-Hydroxyheptadeca-5Z, 8E, 10E-trienoic acid is a natural ligand for leukotriene B4 receptor 2. J Exp Med 205 (2008), 759–766.
56. 56 Masuda, K., Yokomizo, T., Izumi, T., Shimizu, T., cDNA cloning and characterization of guinea-pig leukotriene B4 receptor. Biochem J 342:Pt 1 (1999), 79–85.
57. 57 Toda, A., Yokomizo, T., Masuda, K., Nakao, A., Izumi, T., Shimizu, T., Cloning and characterization of rat leukotriene B(4) receptor. Biochem Biophys Res Commun 262 (1999), 806–812.
58. 58 Iizuka, Y., Yokomizo, T., Terawaki, K., Komine, M., Tamaki, K., Shimizu, T., Characterization of a mouse second leukotriene B4 receptor, mBLT2: BLT2-dependent ERK activation and cell migration of primary mouse keratinocytes. J Biol Chem 280 (2005), 24816–24823.
59. 59 Back, M., Bu, D.X., Bränström, R., Sheikine, Y., Yan, Z.Q., Hansson, G.K., Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci U S A 102 (2005), 17501–17506.
60. 60 Qiu, H., Johansson, A.S., Sjöström, M., Wan, M., Schröder, O., Palmblad, J., et al. Differential induction of BLT receptor expression on human endothelial cells by lipopolysaccharide, cytokines, and leukotriene B4. Proc Natl Acad Sci U S A 103 (2006), 6913–6918.
61. 61 Sun, R., Ba, X., Cui, L., Xue, Y., Zeng, X., Leukotriene B4 regulates proliferation and differentiation of cultured rat myoblasts via the BLT1 pathway. Mol Cells 27 (2009), 403–408.
62. 62 Wada, K., Arita, M., Nakajima, A., Katayama, K., Kudo, C., Kamisaki, Y., et al. Leukotriene B4 and lipoxin A4 are regulatory signals for neural stem cell proliferation and differentiation. FASEB J 20 (2006), 1785–1792.
63. 63 Liu, M., Saeki, K., Matsunobu, T., Okuno, T., Koga, T., Sugimoto, Y., et al. 12-hydroxyheptadecatrienoic acid promotes epidermal wound healing by accelerating keratinocyte migration via the BLT2 receptor. J Exp Med 211 (2014), 1063–1078.
64. 64 Brink, C., Dahlén, S.E., Drazen, J., Evans, J.F., Hay, D.W., Nicosia, S., et al. International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol Rev 55 (2003), 195–227.
65. 65 Haribabu, B., Zhelev, D.V., Pridgen, B.C., Richardson, R.M., Ali, H., Snyderman, R., Chemoattractant receptors activate distinct pathways for chemotaxis and secretion. Role of G-protein usage. J Biol Chem 274 (1999), 37087–37092.
66. 66 Sabirsh, A., Bristulf, J., Owman, C., Exploring the pharmacology of the leukotriene B4 receptor BLT1, without the confounding effects of BLT2. Eur J Pharmacol 499 (2004), 53–65.
67. 67 Heller, E.A., Liu, E., Tager, A.M., Sinha, S., Roberts, J.D., Koehn, S.L., et al. Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment. Circulation 112 (2005), 578–586.
68. 68 Lee, J.W., Kim, J.H., Activation of the leukotriene B4 receptor 2-reactive oxygen species (BLT2-ROS) cascade following detachment confers anoikis resistance in prostate cancer cells. J Biol Chem 288 (2013), 30054–30063.
69. 69 Sanchez-Galan, E., Gómez-Hernández, A., Vidal, C., Martín-Ventura, J.L., Blanco-Colio, L.M., Muñoz-García, B., et al. Leukotriene B4 enhances the activity of nuclear factor-kappaB pathway through BLT1 and BLT2 receptors in atherosclerosis. Cardiovasc Res 81 (2009), 216–225.
70. 70 Serezani, C.H., Lewis, C., Jancar, S., Peters-Golden, M., Leukotriene B4 amplifies NF-kappaB activation in mouse macrophages by reducing SOCS1 inhibition of MyD88 expression. J Clin Invest 121 (2011), 671–682.
71. 71 Csoma, Z., Kharitonov, S.A., Balint, B., Bush, A., Wilson, N.M., Barnes, P.J., Increased leukotrienes in exhaled breath condensate in childhood asthma. Am J Respir Crit Care Med 166 (2002), 1345–1349.
72. 72 O'Driscoll, B.R., Cromwell, O., Kay, A.B., Sputum leukotrienes in obstructive airways diseases. Clin Exp Immunol 55 (1984), 397–404.
73. 73 Sampson, A.P., Castling, D.P., Green, C.P., Price, J.F., Persistent increase in plasma and urinary leukotrienes after acute asthma. Arch Dis Child 73 (1995), 221–225.
74. 74 Shindo, K., Matsumoto, Y., Hirai, Y., Sumitomo, M., Amano, T., Miyakawa, K., et al. Measurement of leukotriene B4 in arterial blood of asthmatic patients during wheezing attacks. J Intern Med 228 (1990), 91–96.
75. 75 Wardlaw, A.J., Hay, H., Cromwell, O., Collins, J.V., Kay, A.B., Leukotrienes, LTC4 and LTB4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. J Allergy Clin Immunol 84 (1989), 19–26.
76. 76 Wenzel, S.E., Trudeau, J.B., Kaminsky, D.A., Cohn, J., Martin, R.J., Westcott, J.Y., Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Respir Crit Care Med 152 (1995), 897–905.
77. 77 Seymour, M.L., Rak, S., Aberg, D., Riise, G.C., Penrose, J.F., Kanaoka, Y., et al. Leukotriene and prostanoid pathway enzymes in bronchial biopsies of seasonal allergic asthmatics. Am J Respir Crit Care Med 164 (2001), 2051–2056.
78. 78 Zaitsu, M., Hamasaki, Y., Matsuo, M., Ichimaru, T., Fujita, I., Ishii, E., Leukotriene synthesis is increased by transcriptional up-regulation of 5-lipoxygenase, leukotriene A4 hydrolase, and leukotriene C4 synthase in asthmatic children. J Asthma 40 (2003), 147–154.
79. 79 Gabrijelcic, J., Acuña, A., Profita, M., Paternò, A., Chung, K.F., Vignola, A.M., et al. Neutrophil airway influx by platelet-activating factor in asthma: role of adhesion molecules and LTB4 expression. Eur Respir J 22 (2003), 290–297.
80. 80 Bruijnzeel, P.L., Warringa, R.A., Kok, P.T., Kreukniet, J., Inhibition of neutrophil and eosinophil induced chemotaxis by nedocromil sodium and sodium cromoglycate. Br J Pharmacol 99 (1990), 798–802.
81. 81 Hilberg, T., Deigner, H.P., Möller, E., Claus, R.A., Ruryk, A., Gläser, D., et al. Transcription in response to physical stress–clues to the molecular mechanisms of exercise-induced asthma. FASEB J 19 (2005), 1492–1494.
82. 82 Sumimoto, H., Takeshige, K., Minakami, S., Superoxide production of human polymorphonuclear leukocytes stimulated by leukotriene B4. Biochim Biophys Acta 803 (1984), 271–277.
83. 83 Lamblin, C., Gosset, P., Tillie-Leblond, I., Saulnier, F., Marquette, C.H., Wallaert, B., et al. Bronchial neutrophilia in patients with noninfectious status asthmaticus. Am J Respir Crit Care Med 157 (1998), 394–402.
84. 84 Sur, S., Crotty, T.B., Kephart, G.M., Hyma, B.A., Colby, T.V., Reed, C.E., et al. Sudden-onset fatal asthma. A distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa?. Am Rev Respir Dis 148 (1993), 713–719.
85. 85 Bousquet, J., Chanez, P., Lacoste, J.Y., Barnéon, G., Ghavanian, N., Enander, I., et al. Eosinophilic inflammation in asthma. N Engl J Med 323 (1990), 1033–1039.
86. 86 Lee, J.J., Dimina, D., Macias, M.P., Ochkur, S.I., McGarry, M.P., O'Neill, K.R., et al. Defining a link with asthma in mice congenitally deficient in eosinophils. Science 305 (2004), 1773–1776.
87. 87 Miyahara, N., Takeda, K., Miyahara, S., Matsubara, S., Koya, T., Joetham, A., et al. Requirement for leukotriene B4 receptor 1 in allergen-induced airway hyperresponsiveness. Am J Respir Crit Care Med 172 (2005), 161–167.
88. 88 Miyahara, N., Takeda, K., Miyahara, S., Taube, C., Joetham, A., Koya, T., et al. Leukotriene B4 receptor-1 is essential for allergen-mediated recruitment of CD8+ T cells and airway hyperresponsiveness. J Immunol 174 (2005), 4979–4984.
89. 89 Terawaki, K., Yokomizo, T., Nagase, T., Toda, A., Taniguchi, M., Hashizume, K., et al. Absence of leukotriene B4 receptor 1 confers resistance to airway hyperresponsiveness and Th2-type immune responses. J Immunol 175 (2005), 4217–4225.
90. 90 Gelfand, E.W., Dakhama, A., CD8+ T lymphocytes and leukotriene B4: novel interactions in the persistence and progression of asthma. J Allergy Clin Immunol 117 (2006), 577–582.
91. 91 Islam, S.A., Thomas, S.Y., Hess, C., Medoff, B.D., Means, T.K., Brander, C., et al. The leukotriene B4 lipid chemoattractant receptor BLT1 defines antigen-primed T cells in humans. Blood 107 (2006), 444–453.
92. 92 Evans, D.J., Barnes, P.J., Spaethe, S.M., van Alstyne, E.L., Mitchell, M.I., O'Connor, B.J., Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma. Thorax 51 (1996), 1178–1184.
93. 93 Asanuma, F., Kuwabara, K., Arimura, A., Furue, Y., Fleisch, J.H., Hori, Y., Effects of leukotriene B4 receptor antagonist, LY293111Na, on antigen-induced bronchial hyperresponsiveness and leukocyte infiltration in sensitized guinea pigs. Inflamm Res 50 (2001), 136–141.
94. 94 Turner, C.R., Breslow, R., Conklyn, M.J., Andresen, C.J., Patterson, D.K., Lopez-Anaya, A., et al. In vitro and in vivo effects of leukotriene B4 antagonism in a primate model of asthma. J Clin Invest 97 (1996), 381–387.
95. 95 Cho, K.J., Seo, J.M., Shin, Y., Yoo, M.H., Park, C.S., Lee, S.H., et al. Blockade of airway inflammation and hyperresponsiveness by inhibition of BLT2, a low-affinity leukotriene B4 receptor. Am J Respir Cell Mol Biol 42 (2010), 294–303.
96. 96 Matsunaga, Y., Fukuyama, S., Okuno, T., Sasaki, F., Matsunobu, T., Asai, Y., et al. Leukotriene B4 receptor BLT2 negatively regulates allergic airway eosinophilia. FASEB J 27 (2013), 3306–3314.
97. 97 Hallstrand, T.S., Henderson, W.R. Jr., An update on the role of leukotrienes in asthma. Curr Opin Allergy Clin Immunol 10 (2010), 60–66.
98. 98 Arm, J.P., Horton, C.E., House, F., Clark, T.J., Spur, B.W., Lee, T.H., Enhanced generation of leukotriene B4 by neutrophils stimulated by unopsonized zymosan and by calcium ionophore after exercise-induced asthma. Am Rev Respir Dis 138 (1988), 47–53.
99. 99 Lehnigk, B., Rabe, K.F., Dent, G., Herst, R.S., Carpentier, P.J., Magnussen, H., Effects of a 5-lipoxygenase inhibitor, ABT-761, on exercise-induced bronchoconstriction and urinary LTE4 in asthmatic patients. Eur Respir J 11 (1998), 617–623.
100. 100 Juergens, U.R., Christiansen, S.C., Stevenson, D.D., Zuraw, B.L., Inhibition of monocyte leukotriene B4 production after aspirin desensitization. J Allergy Clin Immunol 96 (1995), 148–156.
101. 101 Cap, P., Maly, M., Pehal, F., Pelikan, Z., Exhaled leukotrienes and bronchial responsiveness to methacholine in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 102 (2009), 103–109.
102. 102 Profita, M., Montuschi, P., Bonanno, A., Riccobono, L., Montalbano, A.M., Ciabattoni, G., et al. Novel perspectives in the detection of oral and nasal oxidative stress and inflammation in pediatric united airway diseases. Int J Immunopathol Pharmacol 23 (2010), 1211–1219.
103. 103 Tanou, K., Koutsokera, A., Kiropoulos, T.S., Maniati, M., Papaioannou, A.I., Georga, K., et al. Inflammatory and oxidative stress biomarkers in allergic rhinitis: the effect of smoking. Clin Exp Allergy 39 (2009), 345–353.
104. 104 Sousa, A.R., Parikh, A., Scadding, G., Corrigan, C.J., Lee, T.H., Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 347 (2002), 1493–1499.
105. 105 Dumitru, A.F., Shamji, M., Wagenmann, M., Hindersin, S., Scheckenbach, K., Greve, J., et al. Petasol butenoate complex (Ze 339) relieves allergic rhinitis-induced nasal obstruction more effectively than desloratadine. J Allergy Clin Immunol 127 (2011), 1515–1521 e1516.
106. 106 Kumar, N.S., Schaefer, P.A., Lark, G., Frieri, M., Late phase response during nasal challenge: effect of astemizole on leukotriene B4 levels. Allergy Asthma Proc 17 (1996), 93–99.
107. 107 Chari, S., Clark-Loeser, L., Shupack, J., Washenik, K., A role for leukotriene antagonists in atopic dermatitis?. Am J Clin Dermatol 2 (2001), 1–6.
108. 108 Koro, O., Furutani, K., Hide, M., Yamada, S., Yamamoto, S., Chemical mediators in atopic dermatitis: involvement of leukotriene B4 released by a type I allergic reaction in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol 103 (1999), 663–670.
109. 109 Sadik, C.D., Sezin, T., Kim, N.D., Leukotrienes orchestrating allergic skin inflammation. Exp Dermatol 22 (2013), 705–709.
110. 110 Fogh, K., Herlin, T., Kragballe, K., Eicosanoids in skin of patients with atopic dermatitis: prostaglandin E2 and leukotriene B4 are present in biologically active concentrations. J Allergy Clin Immunol 83 (1989), 450–455.
111. 111 Reilly, D.M., Parslew, R., Sharpe, G.R., Powell, S., Green, M.R., Inflammatory mediators in normal, sensitive and diseased skin types. Acta Derm Venereol 80 (2000), 171–174.
112. 112 Ruzicka, T., Simmet, T., Peskar, B.A., Ring, J., Skin levels of arachidonic acid-derived inflammatory mediators and histamine in atopic dermatitis and psoriasis. J Invest Dermatol 86 (1986), 105–108.
113. 113 Okano-Mitani, H., Ikai, K., Imamura, S., Leukotriene A4 hydrolase in peripheral leukocytes of patients with atopic dermatitis. Arch Dermatol Res 288 (1996), 168–172.
114. 114 Kanda, N., Watanabe, S., Leukotriene B(4) enhances tumour necrosis factor-alpha-induced CCL27 production in human keratinocytes. Clin Exp Allergy 37 (2007), 1074–1082.
115. 115 Breathnach, R., Donahy, C., Jones, B.R., Bloomfield, F.J., Increased leukotriene B(4) production, complement C3 conversion and acid hydrolase enzyme concentrations in different leucocyte sub-populations of dogs with atopic dermatitis. Vet J 171 (2006), 106–113.
116. 116 Schlotter, Y.M., Riemers, F.M., Rutten, V.P., Knol, E.F., Willemse, T., Enzymes involved in the conversion of arachidonic acid to eicosanoids in the skin of atopic dogs. Exp Dermatol 19 (2010), e317–e319.
117. 117 Oyoshi, M.K., He, R., Li, Y., Mondal, S., Yoon, J., Afshar, R., et al. Leukotriene B4-driven neutrophil recruitment to the skin is essential for allergic skin inflammation. Immunity 37 (2012), 747–758.
118. 118 Andoh, T., Saito, A., Kuraishi, Y., Leukotriene B(4) mediates sphingosylphosphorylcholine-induced itch-associated responses in mouse skin. J Invest Dermatol 129 (2009), 2854–2860.
119. 119 Andoh, T., Haza, S., Saito, A., Kuraishi, Y., Involvement of leukotriene B4 in spontaneous itch-related behaviour in NC mice with atopic dermatitis-like skin lesions. Exp Dermatol 20 (2011), 894–898.
120. 120 Schultz, B.L., Pharmacology of ocular allergy. Curr Opin Allergy Clin Immunol 6 (2006), 383–389.
121. 121 Spada, C.S., Woodward, D.F., Hawley, S.B., Nieves, A.L., Leukotrienes cause eosinophil emigration into conjunctival tissue. Prostaglandins 31 (1986), 795–809.
122. 122 Garceau, D., Ford-Hutchinson, A.W., Charleson, S., 5-Lipoxygenase inhibitors and allergic conjunctivitis reactions in the guinea-pig. Eur J Pharmacol 143 (1987), 1–7.
123. 123 Nathan, H., Naveh, N., Meyer, E., Levels of prostaglandin E2 and leukotriene B4 in tears of vernal conjunctivitis patients during a therapeutic trial with indomethacin. Doc Ophthalmol 85 (1994), 247–257.
124. 124 Akman, A., Irkec, M., Orhan, M., Effects of lodoxamide, disodium cromoglycate and fluorometholone on tear leukotriene levels in vernal keratoconjunctivitis. Eye (Lond) 12:Pt 2 (1998), 291–295.
125. 125 Akman, A., Irkec, M., Orhan, M., Erdener, U., Effect of lodoxamide on tear leukotriene levels in giant papillary conjunctivitis associated with ocular prosthesis. Ocul Immunol Inflamm 6 (1998), 179–184.
126. 126 Andoh, T., Sakai, K., Urashima, M., Kitazawa, K., Honma, A., Kuraishi, Y., Involvement of leukotriene B4 in itching in a mouse model of ocular allergy. Exp Eye Res 98 (2012), 97–103.
127. 127 Murphy, R.C., Hammarstrom, S., Samuelsson, B., Leukotriene, C., a slow-reacting substance from murine mastocytoma cells. Proc Natl Acad Sci U S A 76 (1979), 4275–4279.
128. 128 Dahlen, S.E., Hansson, G., Hedqvist, P., Björck, T., Granström, E., Dahlén, B., Allergen challenge of lung tissue from asthmatics elicits bronchial contraction that correlates with the release of leukotrienes C4, D4, and E4. Proc Natl Acad Sci U S A 80 (1983), 1712–1716.
129. 129 Coleman, R.A., Eglen, R.M., Jones, R.L., Narumiya, S., Shimizu, T., Smith, W.L., et al. Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature. Adv Prostaglandin Thromboxane Leukot Res 23 (1995), 283–285.
130. 130 Tudhope, S.R., Cuthbert, N.J., Abram, T.S., Jennings, M.A., Maxey, R.J., Thompson, A.M., et al. BAY u9773, a novel antagonist of cysteinyl-leukotrienes with activity against two receptor subtypes. Eur J Pharmacol 264 (1994), 317–323.
131. 131 Hui, Y., Yang, G., Galczenski, H., Figueroa, D.J., Austin, C.P., Copeland, N.G., et al. The murine cysteinyl leukotriene 2 (CysLT2) receptor. cDNA and genomic cloning, alternative splicing, and in vitro characterization. J Biol Chem 276 (2001), 47489–47495.
132. 132 Lynch, K.R., O'Neill, G.P., Liu, Q., Im, D.S., Sawyer, N., Metters, K.M., et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 399 (1999), 789–793.
133. 133 Sarau, H.M., Ames, R.S., Chambers, J., Ellis, C., Elshourbagy, N., Foley, J.J., et al. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol Pharmacol 56 (1999), 657–663.
134. 134 Heise, C.E., O'Dowd, B.F., Figueroa, D.J., Sawyer, N., Nguyen, T., Im, D.S., et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 275 (2000), 30531–30536.
135. 135 Nothacker, H.P., Wang, Z., Zhu, Y., Reinscheid, R.K., Lin, S.H., Civelli, O., Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. Mol Pharmacol 58 (2000), 1601–1608.
136. 136 Maekawa, A., Kanaoka, Y., Lam, B.K., Austen, K.F., Identification in mice of two isoforms of the cysteinyl leukotriene 1 receptor that result from alternative splicing. Proc Natl Acad Sci U S A 98 (2001), 2256–2261.
137. 137 Takasaki, J., Kamohara, M., Matsumoto, M., Saito, T., Sugimoto, T., Ohishi, T., et al. The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT(2) receptor. Biochem Biophys Res Commun 274 (2000), 316–322.
138. 138 Figueroa, D.J., Breyer, R.M., Defoe, S.K., Kargman, S., Daugherty, B.L., Waldburger, K., et al. Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes. Am J Respir Crit Care Med 163 (2001), 226–233.
139. 139 Mellor, E.A., Maekawa, A., Austen, K.F., Boyce, J.A., Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells. Proc Natl Acad Sci U S A 98 (2001), 7964–7969.
140. 140 Kamohara, M., Takasaki, J., Matsumoto, M., Matsumoto, Si, Saito, T., Soga, T., et al. Functional characterization of cysteinyl leukotriene CysLT(2) receptor on human coronary artery smooth muscle cells. Biochem Biophys Res Commun 287 (2001), 1088–1092.
141. 141 Gronert, K., Martinsson-Niskanen, T., Ravasi, S., Chiang, N., Serhan, C.N., Selectivity of recombinant human leukotriene D(4), leukotriene B(4), and lipoxin A(4) receptors with aspirin-triggered 15-epi-LXA(4) and regulation of vascular and inflammatory responses. Am J Pathol 158 (2001), 3–9.
142. 142 Mita, H., Hasegawa, M., Saito, H., Akiyama, K., Levels of cysteinyl leukotriene receptor mRNA in human peripheral leucocytes: significantly higher expression of cysteinyl leukotriene receptor 2 mRNA in eosinophils. Clin Exp Allergy 31 (2001), 1714–1723.
143. 143 Early, S.B., Barekzi, E., Negri, J., Hise, K., Borish, L., Steinke, J.W., Concordant modulation of cysteinyl leukotriene receptor expression by IL-4 and IFN-gamma on peripheral immune cells. Am J Respir Cell Mol Biol 36 (2007), 715–720.
144. 144 Capra, V., Accomazzo, M.R., Ravasi, S., Parenti, M., Macchia, M., Nicosia, S., et al. Involvement of prenylated proteins in calcium signaling induced by LTD4 in differentiated U937 cells. Prostagl Other Lipid Mediat 71 (2003), 235–251.
145. 145 Hoshino, M., Izumi, T., Shimizu, T., Leukotriene D4 activates mitogen-activated protein kinase through a protein kinase Calpha-Raf-1-dependent pathway in human monocytic leukemia THP-1 cells. J Biol Chem 273 (1998), 4878–4882.
146. 146 Saussy, D.L. Jr., Sarau, H.M., Foley, J.J., Mong, S., Crooke, S.T., Mechanisms of leukotriene E4 partial agonist activity at leukotriene D4 receptors in differentiated U-937 cells. J Biol Chem 264 (1989), 19845–19855.
147. 147 Sjolander, A., Gronroos, E., Hammarstrom, S., Andersson, T., Leukotriene D4 and E4 induce transmembrane signaling in human epithelial cells. Single cell analysis reveals diverse pathways at the G-protein level for the influx and the intracellular mobilization of Ca2+. J Biol Chem 265 (1990), 20976–20981.
148. 148 Singh, R.K., Gupta, S., Dastidar, S., Ray, A., Cysteinyl leukotrienes and their receptors: molecular and functional characteristics. Pharmacology 85 (2010), 336–349.
149. 149 Capra, V., Thompson, M.D., Sala, A., Cole, D.E., Folco, G., Rovati, G.E., Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends. Med Res Rev 27 (2007), 469–527.
150. 150 Kanaoka, Y., Maekawa, A., Austen, K.F., Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand. J Biol Chem 288 (2013), 10967–10972.
151. 151 Haberal, I., Corey, J.P., The role of leukotrienes in nasal allergy. Otolaryngol Head Neck Surg 129 (2003), 274–279.
152. 152 Dahlen, S.E., Hedqvist, P., Hammarstrom, S., Samuelsson, B., Leukotrienes are potent constrictors of human bronchi. Nature 288 (1980), 484–486.
153. 153 Bisgaard, H., Groth, S., Bronchial effects of leukotriene D4 inhalation in normal human lung. Clin Sci (Lond) 72 (1987), 585–592.
154. 154 Oosaki, R., Mizushima, Y., Kawasaki, A., Kashii, T., Mita, H., Shida, T., et al. Urinary excretion of leukotriene E4 and 11-dehydrothromboxane B2 in patients with spontaneous asthma attacks. Int Arch Allergy Immunol 114 (1997), 373–378.
155. 155 O'Byrne, P.M., Leukotrienes in the pathogenesis of asthma. Chest 111 (1997), 27S–34.
156. 156 O'Byrne, P.M., Israel, E., Drazen, J.M., Antileukotrienes in the treatment of asthma. Ann Intern Med 127 (1997), 472–480.
157. 157 Borish, L., The role of leukotrienes in upper and lower airway inflammation and the implications for treatment. Ann Allergy Asthma Immunol 88 (2002), 16–22.
158. 158 Dahlen, S.E., Björk, J., Hedqvist, P., Arfors, K.E., Hammarström, S., Lindgren, J.A., et al. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci U S A 78 (1981), 3887–3891.
159. 159 Joris, I., Majno, G., Corey, E.J., Lewis, R.A., The mechanism of vascular leakage induced by leukotriene E4. Endothelial contraction. Am J Pathol 126 (1987), 19–24.
160. 160 Marom, Z., Shelhamer, J.H., Bach, M.K., Morton, D.R., Kaliner, M., Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis 126 (1982), 449–451.
161. 161 Bisgaard, H., Pedersen, M., SRS-A leukotrienes decrease the activity of human respiratory cilia. Clin Allergy 17 (1987), 95–103.
162. 162 Hay, D.W., Torphy, T.J., Undem, B.J., Cysteinyl leukotrienes in asthma: old mediators up to new tricks. Trends Pharmacol Sci 16 (1995), 304–309.
163. 163 Yang, G., Haczku, A., Chen, H., Martin, V., Galczenski, H., Tomer, Y., et al. Transgenic smooth muscle expression of the human CysLT1 receptor induces enhanced responsiveness of murine airways to leukotriene D4. Am J Physiol Lung Cell Mol Physiol 286 (2004), L992–L1001.
164. 164 Ellis, J.L., Undem, B.J., Role of cysteinyl-leukotrienes and histamine in mediating intrinsic tone in isolated human bronchi. Am J Respir Crit Care Med 149 (1994), 118–122.
165. 165 Watson, N., Magnussen, H., Rabe, K.F., Inherent tone of human bronchus: role of eicosanoids and the epithelium. Br J Pharmacol 121 (1997), 1099–1104.
166. 166 Tohda, Y., Nakahara, H., Kubo, H., Haraguchi, R., Fukuoka, M., Nakajima, S., et al. Effects of ONO-1078 (pranlukast) on cytokine production in peripheral blood mononuclear cells of patients with bronchial asthma. Clin Exp Allergy 29 (1999), 1532–1536.
167. 167 Lee, E., Robertson, T., Smith, J., Kilfeather, S., Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals. Am J Respir Crit Care Med 161 (2000), 1881–1886.
168. 168 Nagata, M., Sedgwick, J.B., Kita, H., Busse, W.W., Granulocyte macrophage colony-stimulating factor augments ICAM-1 and VCAM-1 activation of eosinophil function. Am J Respir Cell Mol Biol 19 (1998), 158–166.
169. 169 Hui, Y., Funk, C.D., Cysteinyl leukotriene receptors. Biochem Pharmacol 64 (2002), 1549–1557.
170. 170 Hui, Y., Cheng, Y., Smalera, I., Jian, W., Goldhahn, L., Fitzgerald, G.A., et al. Directed vascular expression of human cysteinyl leukotriene 2 receptor modulates endothelial permeability and systemic blood pressure. Circulation 110 (2004), 3360–3366.
171. 171 Hallstrand, T.S., Moody, M.W., Aitken, M.L., Henderson, W.R. Jr., Airway immunopathology of asthma with exercise-induced bronchoconstriction. J Allergy Clin Immunol 116 (2005), 586–593.
172. 172 Bikov, A., Gajdócsi, R., Huszár, É., Szili, B., Lázár, Z., Antus, B., et al. Exercise increases exhaled breath condensate cysteinyl leukotriene concentration in asthmatic patients. J Asthma 47 (2010), 1057–1062.
173. 173 Spector, S.L., Wangaard, C.H., Farr, R.S., Aspirin and concomitant idiosyncrasies in adult asthmatic patients. J Allergy Clin Immunol 64 (1979), 500–506.
174. 174 Gyllfors, P., Bochenek, G., Overholt, J., Drupka, D., Kumlin, M., Sheller, J., et al. Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. J Allergy Clin Immunol 111 (2003), 1116–1121.
175. 175 Stevenson, D.D., Simon, R.A., Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 108 (2001), 47–51.
176. 176 Antczak, A., Montuschi, P., Kharitonov, S., Gorski, P., Barnes, P.J., Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am J Respir Crit Care Med 166 (2002), 301–306.
177. 177 Christie, P.E., Tagari, P., Ford-Hutchinson, A.W., Charlesson, S., Chee, P., Arm, J.P., et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 143 (1991), 1025–1029.
178. 178 Sladek, K., Szczeklik, A., Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma. Eur Respir J 6 (1993), 391–399.
179. 179 Swierczynska, M., Nizankowska-Mogilnicka, E., Zarychta, J., Gielicz, A., Szczeklik, A., Nasal versus bronchial and nasal response to oral aspirin challenge: clinical and biochemical differences between patients with aspirin-induced asthma/rhinitis. J Allergy Clin Immunol 112 (2003), 995–1001.
180. 180 Adamjee, J., Suh, Y.J., Park, H.S., Choi, J.H., Penrose, J.F., Lam, B.K., et al. Expression of 5-lipoxygenase and cyclooxygenase pathway enzymes in nasal polyps of patients with aspirin-intolerant asthma. J Pathol 209 (2006), 392–399.
181. 181 Cowburn, A.S., Sladek, K., Soja, J., Adamek, L., Nizankowska, E., Szczeklik, A., et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 101 (1998), 834–846.
182. 182 Laidlaw, T.M., Kidder, M.S., Bhattacharyya, N., Xing, W., Shen, S., Milne, G.L., et al. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood 119 (2012), 3790–3798.
183. 183 Steinke, J.W., Negri, J., Liu, L., Payne, S.C., Borish, L., Aspirin activation of eosinophils and mast cells: implications in the pathogenesis of aspirin-exacerbated respiratory disease. J Immunol 193 (2014), 41–47.
184. 184 Dahlen, B., Nizankowska, E., Szczeklik, A., Zetterström, O., Bochenek, G., Kumlin, M., et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 157 (1998), 1187–1194.
185. 185 Peters-Golden, M., Gleason, M.M., Togias, A., Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis. Clin Exp Allergy 36 (2006), 689–703.
186. 186 Miadonna, A., Tedeschi, A., Leggieri, E., Lorini, M., Folco, G., Sala, A., et al. Behavior and clinical relevance of histamine and leukotrienes C4 and B4 in grass pollen-induced rhinitis. Am Rev Respir Dis 136 (1987), 357–362.
187. 187 Volovitz, B., Osur, S.L., Bernstein, J.M., Ogra, P.L., Leukotriene C4 release in upper respiratory mucosa during natural exposure to ragweed in ragweed-sensitive children. J Allergy Clin Immunol 82 (1988), 414–418.
188. 188 Kohi, F., Agrawal, D.K., Cheng, J.B., Bewtra, A., Townley, R.G., Olesch, J.W., The development of a sensitive and specific radioreceptor assay for leukotriene B4. Life Sci 42 (1988), 2241–2248.
189. 189 Higashi, N., Taniguchi, M., Mita, H., Ishii, T., Akiyama, K., Nasal blockage and urinary leukotriene E4 concentration in patients with seasonal allergic rhinitis. Allergy 58 (2003), 476–480.
190. 190 Wilson, A.M., White, P.S., Gardiner, Q., Nassif, R., Lipworth, B.J., Effects of leukotriene receptor antagonist therapy in patients with chronic rhinosinusitis in a real life rhinology clinic setting. Rhinology 39 (2001), 142–146.
191. 191 Fauler, J., Neumann, C., Tsikas, D., Frolich, J., Enhanced synthesis of cysteinyl leukotrienes in atopic dermatitis. Br J Dermatol 128 (1993), 627–630.
192. 192 Sansom, J.E., Taylor, G.W., Dollery, C.T., Archer, C.B., Urinary leukotriene E4 levels in patients with atopic dermatitis. Br J Dermatol 136 (1997), 790–791.
193. 193 Hua, Z., Fei, H., Mingming, X., Evaluation and interference of serum and skin lesion levels of leukotrienes in patients with eczema. Prostagl Leukot Essent Fat Acids 75 (2006), 51–55.
194. 194 Capra, V., Ambrosio, M., Riccioni, G., Rovati, G.E., Cysteinyl-leukotriene receptor antagonists: present situation and future opportunities. Curr Med Chem 13 (2006), 3213–3226.
195. 195 Veien, N.K., Busch-Sorensen, M., Stausbol-Gron, B., Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 53 (2005), 147–149.
196. 196 Oyoshi, M.K., He, R., Kanaoka, Y., ElKhal, A., Kawamoto, S., Lewis, C.N., et al. Eosinophil-derived leukotriene C4 signals via type 2 cysteinyl leukotriene receptor to promote skin fibrosis in a mouse model of atopic dermatitis. Proc Natl Acad Sci U S A 109 (2012), 4992–4997.
197. 197 Dartt, D.A., Hodges, R.R., Li, D., Shatos, M.A., Lashkari, K., Serhan, C.N., Conjunctival goblet cell secretion stimulated by leukotrienes is reduced by resolvins D1 and E1 to promote resolution of inflammation. J Immunol 186 (2011), 4455–4466.
198. 198 Lambiase, A., Bonini, S., Rasi, G., Coassin, M., Bruscolini, A., Montelukast, a leukotriene receptor antagonist, in vernal keratoconjunctivitis associated with asthma. Arch Ophthalmol 121 (2003), 615–620.
199. 199 Simons, F.E., Frew, A.J., Ansotegui, I.J., Bochner, B.S., Golden, D.B., Finkelman, F.D., et al. Risk assessment in anaphylaxis: current and future approaches. J Allergy Clin Immunol 120 (2007), S2–S24.
200. 200 Ono, E., Mita, H., Taniguchi, M., Higashi, N., Tsuburai, T., Miyazaki, E., et al. Comparison of cysteinyl leukotriene concentrations between exhaled breath condensate and bronchoalveolar lavage fluid. Clin Exp Allergy 38 (2008), 1866–1874.
201. 201 Ono, E., Taniguchi, M., Mita, H., Akiyama, K., Salicylamide-induced anaphylaxis: increased urinary leukotriene E4 and prostaglandin D2 metabolite. Allergy 63 (2008), 480–482.
202. 202 Maekawa, A., Austen, K.F., Kanaoka, Y., Targeted gene disruption reveals the role of cysteinyl leukotriene 1 receptor in the enhanced vascular permeability of mice undergoing acute inflammatory responses. J Biol Chem 277 (2002), 20820–20824.